Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02145819
Other study ID # PLUS
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2014
Est. completion date September 2019

Study information

Verified date September 2019
Source Universitair Ziekenhuis Brussel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to determine whether spontaneous LH peak is superior to human chorionic gonadotropin before a transfer of a day 3 frozen embryo.


Description:

For surplus embryos after fresh IVF-cycles, cryopreservation has become common medical practice. These frozen embryos are mostly replaced in an artificial cycle with exogenous estrogen and progesterone or in a natural cycle. Often, hCG is administered as an ovulation induction agent for scheduling purposes.

Successful implantation requires a co-ordinated series of events allowing a timely dialogue between a receptive endometrium and the intrusive blastocyst . The period of receptivity is thought to be 3 days in human. It is suggested that blastocyst apposition begins about day LH+6 and is completed by day LH+10

In general, the aim is to transfer the embryo during the 'window of implantation', what is defined as the period during which the uterus is receptive for implantation of the free-lying blastocyst. This has been a subject of debate since many years.

A prospective study by Fatemi et al. (2010) revealed a significantly higher ongoing pregnancy rate after transferring frozen-thawed embryos in natural cycles with a spontaneous LH peak compared with natural cycles controlled by hCG for final oocyte maturation and ovulation (31.1% vs. 14.3%, respectively). In this trial, FrET (frozen embryo transfer) was planned 5 days after the LH surge or 5 days after the administration of 5000IU of hCG.

In order to optimize the synchronization in the hCG group, and therefore enhance the pregnancy rates, the aim is to plan a FrET 6 days after hCG administration instead of 5 days. The rationale behind is that day 3 frozen embryos are thawed the day before embryo transfer, which means they are already at day 4 of the embryonic development.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date September 2019
Est. primary completion date September 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

- Natural cycles, in which a frozen-thawed day 3 embryo is replaced.

- Signed informed consent.

- Regular cycle (i.e. between 26 and 35 days)

- Normal transvaginal ultrasound at screening, without evidence of clinically significant abnormality consistent with finding adequate for ART with respect to uterus and adnexa.

- Embryos frozen by vitrification.

- Single or dual embryo transfer.

Exclusion Criteria:

- Known allergic reactions to progesterone products.

- Intake of experimental drug within 30 days prior to study start.

- Contraindication for pregnancy.

- Embryos of women above 39 years of age at the time of embryo freezing.

- Recipients of oocyte donation cycles

Study Design


Related Conditions & MeSH terms

  • Supervision of Pregnancy Resulting From In-vitro Fertilization

Intervention

Drug:
hCG

Other:
LH peak


Locations

Country Name City State
Belgium Centre of Reproductive Medicine CRG Jette Brussels

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical pregnancy rate We evaluate the pregnancy, at 7 weeks amenorrhoea. Outcome is clinical pregnancy rate 7 weeks
Secondary number of monitoring visits at the clinic per cycle 7 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01608048 - Transcutaneous Electrical Acupoint Stimulation to Improve Pregnancy Rates for Women Undergoing in Vitro Fertilization N/A